Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients

Yonsei Medical Journal

Volumn 54, Issue 1, 2013, Pages 183-188

  Korczowska, Izabela ^a   Lacki, Jan Krzysztof ^b   Hrycaj, Pawel ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b UNIVERSITY OF ZIELONA GÓRA   (Poland)

Author keywords

Cytokines; Infliximab; Markers of bone remodelling; Rheumatoid arthritis

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CYTOKINE; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; METHOTREXATE; OSTEOCALCIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; ANTIRHEUMATIC AGENT; IL6 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BONE MINERAL; BONE REMODELING; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PHYSICAL EXAMINATION; RHEUMATOID ARTHRITIS; URINALYSIS; ARTHRITIS, RHEUMATOID; BLOOD; COMPLICATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE REMODELING; BONE RESORPTION; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; MIDDLE AGED; OSTEOPOROSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I;

EID: 84871295496     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2013.54.1.183     Document Type: Article

References (23)

1. ReferencesPincus T. Rheumatoid arthritis: a medical emergency? Scand J Rheumatol Suppl 1994;100:21-30.
2. Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J Rheumatol 1984;11:158-61.
3. Li X, Yuan FL, Lu WG, Zhao YQ, Li CW, Li JP, et al. The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun 2010;397:131-5.
4. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52.
5. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275:768-75.
6. Kelchtermans H, Schurgers E, Geboes L, Mitera T, Van Damme J, Van Snick J, et al. Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res Ther 2009;11: R122.
7. Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, Kamatani N, et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 2007;9:R96.
8. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
9. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
10. Scali JJ, Visentini S, Salomón J, Sevilla D, Ju YC, Morales E, et al. Rapid and deep control of inflammation in rheumatoid arthritis with infliximab and its correlation with acute-phase reactants. Ann N Y Acad Sci 2007;1110:389-401.
11. Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics 2009;3:183-91.
12. Martin JC, Munro R, Campbell MK, Reid DM. Effects of disease and corticosteroids on appendicular bone mass in postmenopausal women with rheumatoid arthritis: comparison with axial measurements. Br J Rheumatol 1997;36:43-9.
13. Laan RF, van Riel PL, van de Putte LB. Bone mass in patients with rheumatoid arthritis. Ann Rheum Dis 1992;51:826-32.
14. Van Bezooijen RL, Van Der Wee-Pals L, Papapoulos SE, Löwik CW. Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis 2002;61: 870-6.
15. Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005;7:29-37.
16. Taylor PC. Anti-TNFalpha therapy for rheumatoid arthritis: an update. Intern Med 2003;42:15-20.
17. Torikai E, Kageyama Y, Takahashi M, Nagano A. The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis. Mod Rheumatol 2006;16:350-4.
18. Korczowska I, Hrycaj P, Lacki JK. Does infliximab decrease bone turnover in rheumatoid arthritis patients. Joint Bone Spine 2003;70:398-400.
19. Kageyama Y, Kobayashi H, Kato N. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Mod Rheumatol 2009;19:657-62.
20. Greenspan SL, Parker RA, Ferguson L, Rosen HN, MaitlandRamsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998;13:1431-8.
21. Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999;24:237-44.
22. Kageyama Y, Takahashi M, Torikai E, Suzuki M, Ichikawa T, Nagafusa T, et al. Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:505-9.
23. Yago T, Nanke Y, Ichikawa N, Kobashigawa T, Mogi M, Kamatani N, et al. IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem 2009;108:947-55.